Geneva, Switzerland, 13 December 2021, 08:15 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health (FOPH) and that it will receive in this regard a grant of 6.7 million Swiss francs (€6.4 million) to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric (“neuropsychiatric”) symptoms.
https://geneuro.ch/data/news/GN-PR-FOPH-subsidy-EN-13122021-vf.pdf